Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors

FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE)

Read more at globenewswire.com